Boston Scientific Corp (BSX)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $64.27B
Last updated: Nov 17, 2026 at 11:05 AM ET
Boston Scientific Corp (BSX) Earnings: Report Dates and Results
Boston Scientific (BSX) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Boston Scientific reported EPS of $0.73, in line with the $0.73 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BSX has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.5% below the $0.80 reported for the quarter ended Dec 31, 2025.
BSX Earnings Call
The latest BSX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BSX beat 30, missed 6 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $5.14B, up 1.4% from $5.07B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.73 | $0.73 | $0.58 - $0.82 | 0.00% | In line | -2.7% | 24 | 0 up, 11 down | Oct 28, 2026 | $5.14B |
| Jun 30, 2026 | $0.86 | $0.83 | $0.81 - $0.84 | +3.61% | Beat | +14.7% | 23 | 0 up, 10 down | Jul 29, 2026 | $5.44B |
| Mar 31, 2026 | $0.80 | $0.79 | $0.77 - $0.83 | +1.27% | Beat | +6.7% | 26 | 2 up, 4 down | Apr 22, 2026 | $5.20B |
| Dec 31, 2025 | $0.80 | $0.78 | $0.77 - $0.81 | +2.56% | Beat | +14.3% | 27 | 1 up, 0 down | Feb 4, 2026 | $5.29B |
| Sep 30, 2025 | $0.75 | $0.71 | $0.70 - $0.76 | +5.63% | Beat | +19.0% | 26 | 2 up, 3 down | Oct 22, 2025 | $5.07B |
| Jun 30, 2025 | $0.75 | $0.73 | $0.71 - $0.75 | +2.74% | Beat | +21.0% | 25 | 3 up, 0 down | Jul 23, 2025 | $5.06B |
| Mar 31, 2025 | $0.75 | $0.67 | $0.66 - $0.70 | +11.94% | Beat | +33.9% | 26 | 2 up, 0 down | Apr 23, 2025 | $4.66B |
| Dec 31, 2024 | $0.70 | $0.66 | $0.64 - $0.68 | +6.06% | Beat | +27.3% | 26 | 4 up, 2 down | Feb 5, 2025 | $4.56B |
| Sep 30, 2024 | $0.63 | $0.59 | $0.57 - $0.62 | +6.78% | Beat | +26.0% | 27 | 0 up, 0 down | Oct 23, 2024 | $4.21B |
| Jun 30, 2024 | $0.62 | $0.58 | $0.57 - $0.59 | +6.90% | Beat | +17.0% | 27 | 1 up, 0 down | Jul 24, 2024 | $4.12B |
| Mar 31, 2024 | $0.56 | $0.51 | $0.50 - $0.52 | +9.80% | Beat | +19.1% | 26 | 2 up, 1 down | Apr 24, 2024 | $3.86B |
| Dec 31, 2023 | $0.55 | $0.51 | $0.50 - $0.52 | +7.84% | Beat | +22.2% | 26 | 1 up, 0 down | Jan 31, 2024 | $3.73B |
| Sep 30, 2023 | $0.50 | $0.48 | $0.47 - $0.49 | +4.17% | Beat | +16.3% | 26 | 0 up, 0 down | Oct 26, 2023 | $3.53B |
| Jun 30, 2023 | $0.53 | $0.49 | $0.48 - $0.50 | +8.16% | Beat | +20.5% | 27 | 0 up, 0 down | Jul 27, 2023 | $3.60B |
| Mar 31, 2023 | $0.47 | $0.43 | $0.42 - $0.45 | +9.30% | Beat | +20.5% | 24 | 1 up, 0 down | Apr 26, 2023 | $3.39B |
| Dec 31, 2022 | $0.45 | $0.47 | $0.45 - $0.50 | -4.26% | Miss | 0.0% | 22 | 3 up, 0 down | Feb 1, 2023 | $3.24B |
| Sep 30, 2022 | $0.43 | $0.44 | $0.42 - $0.46 | -2.27% | Miss | +4.9% | 24 | 1 up, 1 down | Oct 26, 2022 | $3.17B |
| Jun 30, 2022 | $0.44 | $0.42 | $0.41 - $0.44 | +4.76% | Beat | +10.0% | 23 | 1 up, 1 down | Jul 27, 2022 | $3.24B |
| Mar 31, 2022 | $0.39 | $0.39 | $0.37 - $0.40 | 0.00% | In line | +5.4% | 24 | 1 up, 1 down | Apr 27, 2022 | $3.03B |
| Dec 31, 2021 | $0.45 | $0.44 | $0.43 - $0.47 | +2.27% | Beat | +95.7% | 24 | N/A | Feb 2, 2022 | $3.13B |
| Sep 30, 2021 | $0.41 | $0.40 | $0.38 - $0.41 | +2.50% | Beat | +10.8% | 26 | 0 up, 1 down | Oct 27, 2021 | $2.93B |
| Jun 30, 2021 | $0.40 | $0.37 | $0.36 - $0.38 | +8.11% | Beat | +400.0% | 27 | N/A | Jul 27, 2021 | $3.08B |
| Mar 31, 2021 | $0.37 | $0.31 | $0.28 - $0.32 | +19.35% | Beat | +32.1% | 26 | N/A | Apr 28, 2021 | $2.75B |
| Dec 31, 2020 | $0.23 | $0.31 | $0.26 - $0.37 | -25.81% | Miss | -50.0% | 25 | N/A | Feb 3, 2021 | $2.71B |
| Sep 30, 2020 | $0.37 | $0.25 | $0.12 - $0.32 | +48.00% | Beat | -5.1% | 24 | N/A | Oct 28, 2020 | $2.66B |
| Jun 30, 2020 | $0.08 | -$0.02 | -$0.22 - $0.25 | +500.00% | Beat | -79.5% | 22 | N/A | Jul 29, 2020 | $2.00B |
| Mar 31, 2020 | $0.28 | $0.32 | $0.26 - $0.36 | -12.50% | Miss | -20.0% | 14 | N/A | Apr 29, 2020 | $2.54B |
| Dec 31, 2019 | $0.46 | $0.44 | $0.43 - $0.45 | +4.55% | Beat | +17.9% | 21 | N/A | Feb 5, 2020 | $2.90B |
| Sep 30, 2019 | $0.39 | $0.38 | $0.36 - $0.40 | +2.63% | Beat | +11.4% | 22 | N/A | Oct 23, 2019 | $2.71B |
| Jun 30, 2019 | $0.39 | $0.38 | $0.37 - $0.39 | +2.63% | Beat | -4.9% | 22 | N/A | Jul 24, 2019 | $2.63B |
| Mar 31, 2019 | $0.35 | $0.36 | $0.33 - $0.36 | -2.78% | Miss | +6.1% | 23 | N/A | Apr 24, 2019 | $2.49B |
| Dec 31, 2018 | $0.39 | $0.36 | $0.32 - $0.38 | +8.33% | Beat | +14.7% | 19 | N/A | Feb 6, 2019 | $2.56B |
| Sep 30, 2018 | $0.35 | $0.34 | $0.33 - $0.35 | +2.94% | Beat | +12.9% | 24 | N/A | Oct 24, 2018 | $2.39B |
| Jun 30, 2018 | $0.41 | $0.34 | $0.34 - $0.35 | +20.59% | Beat | +28.1% | 23 | N/A | Jul 25, 2018 | $2.49B |
| Mar 31, 2018 | $0.33 | $0.32 | $0.31 - $0.33 | +3.13% | Beat | +13.8% | 23 | N/A | Apr 25, 2018 | $2.38B |
| Dec 31, 2017 | $0.34 | $0.34 | $0.32 - $0.36 | 0.00% | In line | +13.3% | 22 | N/A | Feb 1, 2018 | $2.41B |
| Sep 30, 2017 | $0.31 | $0.31 | $0.28 - $0.32 | 0.00% | In line | +14.8% | 23 | N/A | Oct 26, 2017 | $2.22B |
| Jun 30, 2017 | $0.32 | $0.31 | $0.30 - $0.32 | +3.23% | Beat | +18.5% | 24 | N/A | Jul 27, 2017 | $2.26B |
| Mar 31, 2017 | $0.29 | $0.30 | N/A | -3.33% | Miss | +3.6% | N/A | N/A | Apr 27, 2017 | $2.16B |
| Dec 31, 2016 | $0.30 | $0.29 | N/A | +3.45% | Beat | +15.4% | N/A | N/A | Feb 2, 2017 | $2.19B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.05, up 21.5% from the year before. It was $1.12 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.05 | +21.5% |
| Dec 31, 2024 | $2.51 | +22.4% |
| Dec 31, 2023 | $2.05 | +19.9% |
| Dec 31, 2022 | $1.71 | +4.9% |
| Dec 31, 2021 | $1.63 | +69.8% |
| Dec 31, 2020 | $0.96 | -39.6% |
| Dec 31, 2019 | $1.59 | +7.4% |
| Dec 31, 2018 | $1.48 | +17.5% |
| Dec 31, 2017 | $1.26 | +12.5% |
| Dec 31, 2016 | $1.12 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,907 | 16 | |
| 2026Q2 | Jun 30, 2026 | 7,234 | 15 | |
| 2026Q1 | Mar 31, 2026 | 6,965 | 16 | |
| 2025Q4 | Dec 31, 2025 | 7,620 | 18 | |
| 2025Q3 | Sep 30, 2025 | 8,009 | 17 | |
| 2025Q2 | Jun 30, 2025 | 7,735 | 14 | |
| 2025Q1 | Mar 31, 2025 | 8,075 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,452 | 19 |
2026Q3 Earnings Call
Opening remarks
Lauren Tengler Vice President, Investor Relations Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer, and John Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and John will be joined by Joe Fitzgerald, Executive Vice President and Group President, Cardiology, and our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q3 2026 results, which included reconciliations of the non-GAAP measures used in this release. The release, as well as reconciliations of the non-GAAP measures used in today's call, can be found on the Investor Relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and divestitures for which there are less than a full period of comparable net sales. Guidance excludes our previously announced agreement to acquire Penumbra, which we expect to close in early 2027. For more information, please refer to the Q3 financial and operating highlights deck, which may be found on the Investor Relations section of our website. On this call, all references to sales and revenue are organic, and relative growth is compared to the same quarter of the prior year unless otherwise specified. This call contains forward-looking statements regarding, among other things, our financial performance, business plans, market expectations, and product performance and development. These statements are based on our current beliefs using information available to us as of today's date and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect or certain risks or uncertainties materialize, actual results could vary materially from those projected by the forward-looking statements. Factors that may cause such differences are discussed in the earnings release we issued earlier this morning and our periodic reports and other filings with the SEC, including the Risk Factors section of our most recent annual report on Form 10-K. Boston Scientific disclaims any intention or obligation to update these forward-looking statements except as required by law. In addition, this call does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval in connection with the proposed transaction with Penumbra. Boston Scientific has filed with the SEC a registration statement on Form S-4 containing a proxy statement of Penumbra and a prospectus of Boston Scientific that contains important information about Penumbra, Boston Scientific, the proposed transaction, and related matters. At this point, I will turn it over to Mike.
Michael F. Mahoney Chairman and CEO Thanks, Lauren. Thank you to everyone for joining us today.
Frequently Asked Questions About BSX
When is Boston Scientific's next earnings date?
Boston Scientific's next earnings report is expected for Feb 2, 2027.
Did BSX beat earnings estimates last quarter?
Boston Scientific reported EPS of $0.73 for the quarter ended Sep 30, 2026, in line with the $0.73 estimate.
What EPS do analysts expect from BSX next quarter?
The consensus EPS estimate for Boston Scientific for the quarter ending Dec 31, 2026 is $0.78 from 26 analysts, with estimates from $0.74 to $0.83.
How often does BSX beat earnings estimates?
Boston Scientific beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +4.23%.
BSX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts